Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors

• ClinicalTrials.gov Identifier: NCT02856503
• Recruitment Status: Withdrawn
• First Posted: August 5, 2016
• Last Update Posted: January 18, 2019
• Sponsor: Eli Avisar
• Information provided by (Responsible Party): Eli Avisar, University of Miami

Study Description

Brief Summary:

High-doses of Vitamin D (VD) may be used as targeted therapy against breast cancer. The investigators will assess the effect of high dose VD on the following biomarkers in the breast cancer cells: VDR, estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (Her2/neu), androgen receptor (AR), as well as epidermal growth factor receptor 1 (EGFR) and Ki-67, as markers of proliferation, and E-cadherin, a marker of invasion and metastasis.

Condition or disease	Intervention/treatment	Phase
Breast Cancer; Invasive Breast Carcinoma; Ductal Carcinoma In-situ	Drug: Vitamin D3	Phase 1; Phase 2

Detailed Description:

This is a phase I/II open-label, non-randomized study. In phase I, a fixed weekly course of oral high-dose Vitamin D (VD) is planned for either 3, 4 or 5 weeks; patients will be sequentially enrolled into 3 groups (A, B or C respectively) in a manner such that no more than two patients may have treatment-limiting toxicities (TLTs).

After the group with the optimal duration of VD therapy to achieve a "favorable response" is determined, phase II will begin enrollment.

Patients must be scheduled to have surgery performed within 2- weeks of the last dose of VD.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I/II Study Evaluating Safety and Effects of Preoperative High-Dose Vitamin D on the Receptors, Biomarkers and Pathological Characteristics of High Grade DCIS or Invasive Breast Cancer.
• Estimated Study Start Date: January 2019
• Estimated Primary Completion Date: January 2023
• Estimated Study Completion Date: January 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase 1 - Group A - VD 3 Weeks; Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 3 weeks.	Drug: Vitamin D3; Weekly oral dose of Vitamin D3 per protocol.; Other Names: Toxiferol; Cholecalciferol
Active Comparator: Phase 1 - Group B - VD 4 Weeks; Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 4 weeks	Drug: Vitamin D3; Weekly oral dose of Vitamin D3 per protocol.; Other Names: Toxiferol; Cholecalciferol
Active Comparator: Phase 1 - Group C - VD 5 Weeks; Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 5 weeks.	Drug: Vitamin D3; Weekly oral dose of Vitamin D3 per protocol.; Other Names: Toxiferol; Cholecalciferol
Experimental: Phase 2 - VD; Weekly oral dose of 50,000 IU Vitamin D3 (VD) therapy for the duration selected from the phase I part of the study.	Drug: Vitamin D3; Weekly oral dose of Vitamin D3 per protocol.; Other Names: Toxiferol; Cholecalciferol

Outcome Measures

Primary Outcome Measures :

1. Phase 1 - Rate of Treatment-Related Toxicity in Subjects [ Time Frame: From Baseline to 30 days (+ 5 days) After Last Dose of Protocol Therapy, About 3 Months ]
   Rate of treatment-related adverse events and other toxicities in subjects.
2. Phase 2 - Rate of Favorable Treatment Response in Subjects Receiving Protocol Therapy Given Within the Optimal Duration Determined in Phase 1. [ Time Frame: Up to 7 Weeks ]

   Rate of subjects achieving a "favorable treatment response" to protocol therapy given within the optimal duration determined in Phase 1. The effect of VD therapy will be assessed in terms of change in expression of VDR, ER, PR, HER2/neu, AR, Ki-67, E-cadherin and EGFR comparing surgical specimen (post-VD treatment) and baseline biopsy specimen (pre-VD treatment). The effect of VD will be described as increased expression, decreased expression or no change in expression of each marker/receptor measured.

   The expression of nuclear receptors/proteins (VDR, Ki-67, ER, PR, AR,) will be scored based on the percentage of positively staining nuclei as follows:

   • 0 (Negative) if <1%
   • +1 (Weak) if >1-10%
   • +2 (Moderate) if >10-50%
   • +3 (Strong) if >50%

   A decrease in the expression of Ki-67 by ≥+1 after treatment is considered a "favorable treatment response".

Secondary Outcome Measures :

1. Phase 1 - Optimal Duration of Once-Weekly Protocol Therapy [ Time Frame: Up to 7 Weeks ]

   The determination of the optimal duration of once-weekly protocol therapy, 3, 4 or 5 weeks, as preoperative treatment to achieve a "favorable" treatment response in subjects with the study disease. The effect of VD therapy will be assessed in terms of change in expression of VDR, ER, PR, HER2/neu, AR, Ki-67, E-cadherin and EGFR comparing surgical specimen (post-VD treatment) and baseline biopsy specimen (pre-VD treatment). The effect of VD will be described as increased expression, decreased expression or no change in expression of each marker/receptor measured.

   The expression of nuclear receptors/proteins (VDR, Ki-67, ER, PR, AR,) will be scored based on the percentage of positively staining nuclei as follows:

   • 0 (Negative) if <1%
   • +1 (Weak) if >1-10%
   • +2 (Moderate) if >10-50%
   • +3 (Strong) if >50%

   A decrease in the expression of Ki-67 by ≥+1 after treatment is considered a "favorable treatment response".

2. Phase 2 - Rate of Treatment-Related Toxicity in Subjects [ Time Frame: From Baseline to 30 days (+ 5 days) After Last Dose of Protocol Therapy, About 3 Months ]
   Rate of treatment-related adverse events and other toxicities in subjects.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patients must have histologically confirmed invasive breast carcinoma (IBC) or high grade (DIN3) Ductal Carcinoma in-situ (DCIS) and be scheduled for primary surgery.
2. Patients must be recommended/scheduled for primary surgery.
3. Female patients 18 years of age or older.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

5. Patients must have normal organ function as defined below:

   • Aspartate aminotransferase (AST/SGOT) < 4 times institutional upper limit of normal.
   • Alanine transaminase (ALT/SGPT) < 4 times institutional upper limit of normal.
   • Serum Bilirubin < 1.5 mg/dl.
   • Serum Alkaline Phosphatase < 4 times institutional upper limit.
   • Creatinine within normal institutional limits OR; Creatinine clearance >/= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
   • Albumin within normal institutional limits
6. Women of childbearing potential (WoCBP) must have a negative (serum or urine) pregnancy test and agree to use barrier contraception while on treatment and for 30-days thereafter.
7. Ability to understand and the willingness to sign a written informed consent document by patient or their legal representatives.

Exclusion Criteria:

1. Previous history of breast cancer diagnosis or treatment.
2. Synchronous bilateral breast cancer.
3. Metastatic breast cancer
4. Patients recommended for neoadjuvant systemic therapy.
5. Patients may not be receiving any other investigational agents or have participated in any investigational drug study within 4 weeks preceding the start of study treatment.
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
7. Concurrent other malignancy
8. Uncontrolled hypertension
9. Chronic cholestatic or alcoholic liver disease
10. Chronic pancreatitis
11. Kidney impairment or renal stones
12. History of parathyroidectomy
13. Hypercalcemia, defined as serum level >11 mg/dl.
14. Abnormal laboratory data for: AST (SGOT), ALT (SGPT), Serum Bilirubin, Alkaline phosphatase, Creatinine and/or Creatinine clearance, and Albumin.
15. Patients receiving medications that are incompatible with VD.
16. Prior or known allergic reaction(s) to Vitamin D or other forms of Vitamin D.
17. Female patients who are pregnant or breast feeding.

Contacts and Locations

Sponsors and Collaborators

Eli Avisar

Investigators

• Principal Investigator: Eli Avisar, MD; University of Miami

More Information

• Responsible Party: Eli Avisar, Professor, University of Miami
• ClinicalTrials.gov Identifier: NCT02856503 History of Changes
• Other Study ID Numbers: 20150288
• First Posted: August 5, 2016
• Last Update Posted: January 18, 2019
• Last Verified: January 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Eli Avisar, University of Miami:

DCIS; IBC; Breast Cancer; Invasive Breast Carcinoma; High Grade Ductal Carcinoma in-situ

Additional relevant MeSH terms:

Carcinoma; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Breast Diseases; Skin Diseases; Adenocarcinoma; Neoplasms, Ductal, Lobular, and Medullary; Breast Carcinoma In Situ; Vitamin D; Ergocalciferols; Cholecalciferol; Vitamins; Micronutrients; Nutrients; Growth Substances; Physiological Effects of Drugs; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents